UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pharmacogenetic Pathway Analysis of Docetaxel Elimination

Clinical pharmacology and therapeutics, 2009-02, Vol.85 (2), p.155-163

2009

Volltextzugriff (PDF)

Abstract ES1-2: The Practical Use of Molecular Profiling: The View of a Medical Oncologist

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.ES1-2-ES1-2

Wolff, AC

2012

Volltextzugriff (PDF)

American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer

Journal of clinical oncology, 2005-10, Vol.23 (30), p.7703-7720

2005

Volltextzugriff (PDF)

Abstract P4-08-35: Young age at diagnosis is associated with worse prognosis in the luminal A breast cancer subtype. A retrospective institutional cohort study

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P4-P4-08-35

2019

Volltextzugriff (PDF)

American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004

Journal of clinical oncology, 2005-01, Vol.23 (3), p.619-629

2005

Volltextzugriff (PDF)

Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial

Journal of clinical oncology, 2023-11, Vol.41 (33), p.5118-5130

2023

Volltextzugriff (PDF)

Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC)

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.S1-S1-04

2013

Volltextzugriff (PDF)

Abstract P5-12-04: A new method of data analysis to derive DNA methylation signatures that stratify risk of recurrence in triple negative breast cancer

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P5-P5-12-04

2019

Volltextzugriff (PDF)

Abstract OT3-02-03: IMMUNe mOdulation in early stage estrogen receptor positive breast cancer treated with neoADjuvant Avelumab, Palbociclib, and Tamoxifen: The ImmunoADAPT study (NCT03573648)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT3-02-03-OT3-02-03

2019

Volltextzugriff (PDF)

A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial

Breast cancer research and treatment, 2018-08, Vol.171 (1), p.121-129

2018

Volltextzugriff (PDF)

Abstract GS6-03: Circulating tumor cells (CTCs) five years after diagnosis are prognostic for late recurrence in operable stage II-III breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.GS6-03-GS6-03

2018

Volltextzugriff (PDF)

Abstract P4-08-09: DNA methylation markers predict recurrence-free interval in triple-negative breast cancer

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P4-P4-08-09

2019

Volltextzugriff (PDF)

Abstract PD2-12: Palbociclib in combination with fulvestrant or tamoxifen as treatment for hormone receptor positive (HR+) metastatic breast cancer (MBC) with prior chemotherapy for advanced disease (TBCRC 035) A phase II study with pharmacodynamics markers

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.PD2-12-PD2-12

2019

Volltextzugriff (PDF)

Abstract P2-05-13: Negative progesterone receptor is associate early breast cancer relapse, even among good prognosis tumors

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P2-P2-05-13

2017

Volltextzugriff (PDF)

Abstract P6-12-21: Breast cancer survivors undergoing survivorship visits at Johns Hopkins are a high-risk population

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P6-P6-12-21

2018

Volltextzugriff (PDF)

Abstract P2-08-14: Dissecting the effect of hormone receptor (HR) status expression in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Exploratory analysis from the ALTTO (BIG 2-06) trial

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P2-P2-08-14

2019

Volltextzugriff (PDF)

Abstract P4-01-16: Detection of plasma tumor DNA (ptDNA) in patients with hormone receptor-positive HER2-negative (HR+HER2-) early breast cancer (EBC) in clinical remission

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P4-P4-01-16

2019

Volltextzugriff (PDF)

Abstract P4-16-09: Effect of simvastatin on cardiac strain in breast cancer patients receiving anthracycline therapy

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P4-P4-16-09

2019

Volltextzugriff (PDF)

Abstract P2-09-12: Independent validation of the HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P2-P2-09-12

2018

Volltextzugriff (PDF)

Abstract P5-23-02: Quality of life (QoL) in male breast cancer (BC): Prospective study of the EORTC10085/TBCRC029/BIG2-07/NABCG International male BC program

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-23-02

2018

Volltextzugriff (PDF)

Abstract P6-03-07: An automated DNA methylation assay (QM-MSP) for rapid breast cancer diagnosis in underdeveloped countries

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P6-P6-03-07

2018

Volltextzugriff (PDF)

Abstract P3-12-02: Predictors of adherence to adjuvant endocrine therapy (ET) for early breast cancer (BC) in a prospective clinic-based cohort

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P3-P3-12-02

2018

Volltextzugriff (PDF)

Abstract S1-02: PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.S1-S1-02

2017

Volltextzugriff (PDF)

Abstract PD5-07: The impact of early lapatinib-induced rash on disease-free and overall survival in patients treated within the ALTTO phase III randomized trial

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.PD5-07-PD5-07

2016

Volltextzugriff (PDF)

Comparative Pharmacokinetics of Weekly and Every-Three-Weeks Docetaxel

Clinical cancer research, 2004-03, Vol.10 (6), p.1976-1983

2004

Volltextzugriff (PDF)

1 – 25 von 138

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(128)
Mit Volltextzugriff
(116)

Publikationsform

Artikel
(133)
Tagungsberichte
(5)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(98)
Life Sciences & Biomedicine
(85)
Humans
(73)
Biological And Medical Sciences
(43)
Female
(39)
Medical Sciences
(39)
Adult
(27)
Oncology
(27)
Middle Aged
(23)
Animals
(18)
Technology
(18)
Male
(17)
Aged
(16)
Breast Neoplasms - Drug Therapy
(16)
Pharmacology. Drug Treatments
(16)
Computer Science
(14)
Computer Science, Information Systems
(14)
Physical Sciences
(14)
Medical Informatics
(13)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pharmacogenetic Pathway Analysis of Docetaxel Elimination

Abstract ES1-2: The Practical Use of Molecular Profiling: The View of a Medical Oncologist

American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer

Abstract P4-08-35: Young age at diagnosis is associated with worse prognosis in the luminal A breast cancer subtype. A retrospective institutional cohort study

American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004

Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial

Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC)

Abstract P5-12-04: A new method of data analysis to derive DNA methylation signatures that stratify risk of recurrence in triple negative breast cancer

Abstract OT3-02-03: IMMUNe mOdulation in early stage estrogen receptor positive breast cancer treated with neoADjuvant Avelumab, Palbociclib, and Tamoxifen: The ImmunoADAPT study (NCT03573648)

A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial

Abstract GS6-03: Circulating tumor cells (CTCs) five years after diagnosis are prognostic for late recurrence in operable stage II-III breast cancer

Abstract P4-08-09: DNA methylation markers predict recurrence-free interval in triple-negative breast cancer

Abstract PD2-12: Palbociclib in combination with fulvestrant or tamoxifen as treatment for hormone receptor positive (HR+) metastatic breast cancer (MBC) with prior chemotherapy for advanced disease (TBCRC 035) A phase II study with pharmacodynamics markers

Abstract P2-05-13: Negative progesterone receptor is associate early breast cancer relapse, even among good prognosis tumors

Abstract P6-12-21: Breast cancer survivors undergoing survivorship visits at Johns Hopkins are a high-risk population

Abstract P2-08-14: Dissecting the effect of hormone receptor (HR) status expression in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Exploratory analysis from the ALTTO (BIG 2-06) trial

Abstract P4-01-16: Detection of plasma tumor DNA (ptDNA) in patients with hormone receptor-positive HER2-negative (HR+HER2-) early breast cancer (EBC) in clinical remission

Abstract P4-16-09: Effect of simvastatin on cardiac strain in breast cancer patients receiving anthracycline therapy

Abstract P2-09-12: Independent validation of the HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer

Abstract P5-23-02: Quality of life (QoL) in male breast cancer (BC): Prospective study of the EORTC10085/TBCRC029/BIG2-07/NABCG International male BC program

Abstract P6-03-07: An automated DNA methylation assay (QM-MSP) for rapid breast cancer diagnosis in underdeveloped countries

Abstract P3-12-02: Predictors of adherence to adjuvant endocrine therapy (ET) for early breast cancer (BC) in a prospective clinic-based cohort

Abstract S1-02: PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy

Abstract PD5-07: The impact of early lapatinib-induced rash on disease-free and overall survival in patients treated within the ALTTO phase III randomized trial

Comparative Pharmacokinetics of Weekly and Every-Three-Weeks Docetaxel

Suchergebnisse filtern